Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort Abstract #1485

Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Aim(s): We evaluated the NETest and CgA in a Dutch cohort and evaluated diagnosis and prediction of disease status
Materials and methods: 20 healthy volunteers and 133 patients with NET were included. G1: n=100, G2: n=33; positive Octreoscan: n=104; non-progressive disease (NPD): n=84, progressive disease (PD): n=49. Transcripts assessment-real-time PCR (ULN: 14%) and CgA-Kryptor (ULN: 100µg/l) were measured. Mann-Whitney tests and ROC-statistics were used. Values expressed as median (range)
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar

To read results and conclusion, please login ...

Further abstracts you may be interested in

#343 PCR Assessment of Carcinoid Lymph Node Metastasis CgA Transcript Outperforms Immunostaining, Tyramide Signal Amplification and H&E and Significantly Upstages Disease
Introduction: Accurate neuroendocrine tumor (NETs) staging is vital for determining therapeutic strategy. Sensitive techniques to facilitate identification of metastases (mets) are of critical clinical relevance.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mark Kidd
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR
#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.
Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Keywords: Biomarker, SSA
#1212 Circulating Gene Transcript Analysis of Pancreatic NETs
Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Authors: Kidd M, Modlin I, Drozdov I, Alaimo D, ...
Keywords: PNET, NETest, PCR